Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence of resistance to recycled NRTIs
Higher HIV viral load and lower CD4 count linked to liver cancer risk
Thailand’s achievements in HIV are not all widely implemented
‘Gentler cure’ technique produces delay in viral rebound in some people taken off HIV therapy
U=U is a human rights issue
People with HIV may benefit from earlier lung cancer screening
Self-testing helps the partners of people with HIV to test, but not to link to care
Co-administration of dolutegravir-based treatment and short course of rifapentine/isoniazid (3HP) well tolerated in people living with HIV
Sixfold increased risk of infant HIV infection and high rates of low birth weight among women with HIV/hepatitis B co-infection
